A Trial of YL-13027 in Combination With Gemcitabine and Nab-paclitaxel in Patients With Refractory Metastatic Pancreatic Cancer
A Phase 1b Trial of YL-13027 in Combination With Gemcitabine and Nab-paclitaxel in Patients With Refractory Metastatic Pancreatic Cancer
Sponsor: 280Bio Inc
Terminated
\<75 % participation
Other Metastatic Pancreatic Cancer trials with similar outcome
Listed as NCT06199466, this PHASE1 trial focuses on Metastatic Pancreatic Cancer and remains terminated or withdrawn. Sponsored by 280Bio Inc, it has been updated 9 times since 2024, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
9 versions recorded-
Jan 2026 — Present [monthly]
Terminated PHASE1
-
Oct 2025 — Jan 2026 [monthly]
Terminated PHASE1
Status: Active Not Recruiting → Terminated
-
May 2025 — Oct 2025 [monthly]
Active Not Recruiting PHASE1
-
Nov 2024 — May 2025 [monthly]
Active Not Recruiting PHASE1
-
Oct 2024 — Nov 2024 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
▶ Show 4 earlier versions
-
Sep 2024 — Oct 2024 [monthly]
Recruiting PHASE1
-
Aug 2024 — Sep 2024 [monthly]
Recruiting PHASE1
-
Jul 2024 — Aug 2024 [monthly]
Recruiting PHASE1
-
Feb 2024 — Jul 2024 [monthly]
Recruiting PHASE1
First recorded
Jan 2024
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- 280Bio Inc
- M.D. Anderson Cancer Center
For direct contact, visit the study record on ClinicalTrials.gov .